Applicability of the Brighton Collaboration Case Definition for seizure after immunization in active and passive surveillance in Canada

Highlights • Canada conducts passive and active syndromic surveillance for vaccine adverse events. • We assessed feasibility of applying standard case definitions to reports of seizure. • 37% of 2009–2011 cases met Brighton Collaboration case definition (BCCD) for seizure. • Applying BCCD was feasib...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2013-11, Vol.31 (48), p.5700-5705
Hauptverfasser:	Top, Karina A, Constantinescu, Cora M, Laflèche, Julie, Bettinger, Julie A, Scheifele, David W, Vaudry, Wendy, Halperin, Scott A, Law, Barbara J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse event following immunization Age Allergy and Immunology Applied microbiology Biological and medical sciences Canada - epidemiology Case definition children Collaboration consciousness Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Epidemiological Monitoring Female fever Fundamental and applied biological sciences. Psychology guidelines Hospitals Humans Immunization Infant Infant, Newborn Jurisdiction Male Microbiology monitoring Pediatrics Public health Retrospective Studies Seizure Seizures - chemically induced Seizures - pathology Surveillance vaccination Vaccination - adverse effects Vaccines Vaccines - administration & dosage Vaccines - adverse effects Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Canada conducts passive and active syndromic surveillance for vaccine adverse events. • We assessed feasibility of applying standard case definitions to reports of seizure. • 37% of 2009–2011 cases met Brighton Collaboration case definition (BCCD) for seizure. • Applying BCCD was feasible when it was included in adverse event reporting forms.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2013.09.048